CO2023017151A2 - Inhibidores de ripk1 de nicotinamida - Google Patents

Inhibidores de ripk1 de nicotinamida

Info

Publication number
CO2023017151A2
CO2023017151A2 CONC2023/0017151A CO2023017151A CO2023017151A2 CO 2023017151 A2 CO2023017151 A2 CO 2023017151A2 CO 2023017151 A CO2023017151 A CO 2023017151A CO 2023017151 A2 CO2023017151 A2 CO 2023017151A2
Authority
CO
Colombia
Prior art keywords
nicotinamide
ripk1
inhibitors
ripk1 inhibitors
compounds
Prior art date
Application number
CONC2023/0017151A
Other languages
English (en)
Inventor
Kevin Patrick Cusack
Michael Zeller Hoemann
David Andrew Kinsman
Sami Osman
James Patrick Stambuli
Maria Anastasia Argiriadi
Ciaran O'reilly
Hannah Dexter
Euan Fordyce
Gallay Steve St
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CO2023017151A2 publication Critical patent/CO2023017151A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción se proporcionan compuestos de la Fórmula (I) y sales farmacéuticamente aceptables de estos, útiles como inhibidores de RIPK1, y composiciones farmacéuticas que los comprenden. Además se proporcionan métodos de uso y preparación. (I
CONC2023/0017151A 2021-08-10 2023-12-11 Inhibidores de ripk1 de nicotinamida CO2023017151A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163231590P 2021-08-10 2021-08-10
PCT/US2022/039689 WO2023018643A1 (en) 2021-08-10 2022-08-08 Nicotinamide ripk1 inhibitors

Publications (1)

Publication Number Publication Date
CO2023017151A2 true CO2023017151A2 (es) 2023-12-29

Family

ID=83439074

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017151A CO2023017151A2 (es) 2021-08-10 2023-12-11 Inhibidores de ripk1 de nicotinamida

Country Status (13)

Country Link
US (1) US11767310B2 (es)
EP (1) EP4301744A1 (es)
JP (2) JP7406672B2 (es)
KR (1) KR20230163568A (es)
CN (1) CN117460722A (es)
AR (1) AR126733A1 (es)
AU (1) AU2022328136A1 (es)
BR (1) BR112023025850A2 (es)
CA (1) CA3219155A1 (es)
CO (1) CO2023017151A2 (es)
IL (1) IL308349A (es)
TW (1) TW202321211A (es)
WO (1) WO2023018643A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4301744A1 (en) 2021-08-10 2024-01-10 AbbVie Inc. Nicotinamide ripk1 inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970705560A (ko) 1995-08-02 1997-10-09 호아껭 우리아치 토렐로 항진균 활성을 갖는 신규한 카르복사미드(new carboxamides with antifungal activity)
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
US7666862B2 (en) 2003-08-15 2010-02-23 Merck & Co., Inc. Mitotic Kinesin Inhibitors
ES2319429T3 (es) 2003-08-15 2009-05-07 MERCK & CO., INC. Inhibidores de cinesina mitotica.
US7112316B1 (en) 2005-08-08 2006-09-26 Uop Llc Process for preparing molecular sieves via continuous addition of nutrients
US20100121048A1 (en) 2006-02-16 2010-05-13 Takanobu Kuroita Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension
ES2360929T3 (es) 2007-09-20 2011-06-10 Amgen Inc. Derivados del ácido 1-(4-(4-bencilbenzamido)-bencil)azetidin-3-carboxílico y compuestos relacionados como moduladores del receptor s1p para el tratamiento de trastornos inmunitarios.
AU2009225869B2 (en) 2008-03-18 2014-01-23 Merck Sharp & Dohme Llc Substituted 4-hydroxypyrimidine-5-carboxamides
MX2011010905A (es) 2009-04-15 2011-11-01 Abbott Lab Compuestos antivirales.
WO2011113707A1 (en) 2010-03-17 2011-09-22 Exxonmobil Chemical Patents Inc. Plasticiser blends and compositions and articles made therefrom
MX367623B (es) 2010-10-20 2019-08-29 Gruenenthal Gmbh 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
WO2013049255A1 (en) 2011-09-26 2013-04-04 Vanderbilt University Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors
TWI637951B (zh) 2013-02-15 2018-10-11 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類
PT3087051T (pt) 2013-12-24 2020-10-21 Oncotartis Inc Compostos de nicotinamida e benzamida e métodos para utilizar os mesmos
KR101555033B1 (ko) 2014-07-28 2015-09-23 충남대학교산학협력단 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
KR101551313B1 (ko) 2014-07-28 2015-09-09 충남대학교산학협력단 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
US20170266199A1 (en) 2014-08-21 2017-09-21 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as rip1 kinase inhibitors as medicaments
JP6772141B2 (ja) 2014-12-24 2020-10-21 ナショナル・インスティチュート・オブ・バイオロジカル・サイエンシズ，ベイジン ネクローシス阻害薬
UY36680A (es) 2015-05-19 2016-12-30 Glaxosmithkline Ip Dev Ltd Amidas heterocíclicas como inhibidores de quinasa
TWI763630B (zh) 2015-07-02 2022-05-11 瑞士商赫孚孟拉羅股份公司 雙環內醯胺及其使用方法
CN108431004B (zh) 2015-10-23 2021-02-12 武田药品工业株式会社 杂环化合物
CN108602809B (zh) 2015-12-04 2022-09-30 戴纳立制药公司 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂
US10961258B2 (en) 2015-12-21 2021-03-30 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as kinase inhibitors
CR20180413A (es) 2016-02-05 2018-12-04 Denali Therapeutics Inc Inhibidores de la proteína quinasa 1 que interactua con el receptor
US20200040025A1 (en) 2016-09-26 2020-02-06 Tufts University Uridine nucleoside derivatives, compositions and methods of use
PT3580220T (pt) 2017-02-13 2022-01-03 Bristol Myers Squibb Co Aminotriazolopiridinas como inibidores de quinase
DE102017211104B3 (de) 2017-06-29 2018-10-18 Bundesdruckerei Gmbh Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung
HUE063896T2 (hu) 2018-05-03 2024-02-28 Rigel Pharmaceuticals Inc RIP1 inhibitorvegyületek, valamint ezek elõállítása és alkalmazása
CN110194772B (zh) 2018-07-02 2022-04-05 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
US20210284647A1 (en) 2018-07-10 2021-09-16 Voronoibio Inc. N-(3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methylphenyl)-5-phenyl-4,5-dihydro-1h-pyrazole-1-carboxamide derivative, and pharmaceutical composition containing same as active ingredient for treating kinase-related diseases
KR20200089219A (ko) 2019-01-15 2020-07-24 보로노이 주식회사 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물
EP4301744A1 (en) 2021-08-10 2024-01-10 AbbVie Inc. Nicotinamide ripk1 inhibitors

Also Published As

Publication number Publication date
AU2022328136A1 (en) 2023-11-30
JP2023549007A (ja) 2023-11-22
WO2023018643A1 (en) 2023-02-16
JP7406672B2 (ja) 2023-12-27
JP2024037892A (ja) 2024-03-19
CN117460722A (zh) 2024-01-26
US11767310B2 (en) 2023-09-26
KR20230163568A (ko) 2023-11-30
IL308349A (en) 2024-01-01
AR126733A1 (es) 2023-11-08
BR112023025850A2 (pt) 2024-03-05
TW202321211A (zh) 2023-06-01
EP4301744A1 (en) 2024-01-10
US20230127127A1 (en) 2023-04-27
CA3219155A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
NI202000078A (es) Compuestos heteroaril tetracíclicos
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
CR11641A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
CO2023017151A2 (es) Inhibidores de ripk1 de nicotinamida
CO6382176A2 (es) Derivados de urea heterociclicos y metodos de uso de los mismos-332
ECSP22038478A (es) Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1
ECSP22038509A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
UY31865A (es) Derivados de urea heterocíclicos y métodos para la utilización de los mismos
CO2021010930A2 (es) Hidroxipiridoxazepinas como activadores de nrf2
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
CO2023000056A2 (es) Derivados de amidopirimidona
UY39588A (es) Pirazolotiazol carboxamidas y usos de estas como inhibidores de pdgfr
CL2022002975A1 (es) Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
DOP2020000088A (es) Derivados de piridinona y su uso como inhibidores selectivos de alk–2.
ECSP18056196A (es) Derivados de indano
CL2023001138A1 (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo inhibidores de galectina-3
CL2023000970A1 (es) Espiro derivados de alfa-d-galactopiranosidos
CL2023002322A1 (es) Derivados de hidroxiheterocicloalquil-carbamoilo
ECSP23075535A (es) Compuestos cíclicos y métodos de uso
CO2024000832A2 (es) Inhibidores de transglutaminasas
CU20100239A7 (es) Derivados de urea heterocíclicos para el tratamiento de las infecciones bacterianas